Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSC | P53634 | 2/20 | 0.39 |
| ▸ | CTSH | P09668 | 1/20 | 0.39 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3077812 | 0.90 | CTSV (0.38) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL5010541 | 0.73 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL11508468 | 0.72 | FFAR1 (0.44) | ALDH1A1SMN1; SMN2CHRNB4CHRNA3HRH1 | |
| SCHEMBL11170273 | 0.70 | CHRNB4 (0.46) | SMN1; SMN2CHRNB4CHRNA3SLC6A2SLC6A3 | |
| SCHEMBL3077907 | 0.70 | CHRNB2 (0.55) | CHRNB4CHRNA3 | |
| SCHEMBL2244976 | 0.70 | USP30 (0.50) | USP30SMN1; SMN2HRH1FFAR4SLC6A2 | |
| SCHEMBL7246918 | 0.70 | CARM1 (0.40) | SMN1; SMN2CHRNB4CHRNA3SLC6A2SLC6A3 | |
| SCHEMBL8601363 | 0.70 | CHRNB4 (0.40) | CTSVCTSLCTSBCTSSCTSK | |
| SCHEMBL1751084 | 0.69 | HRH3 (0.40) | ALDH1A1SMN1; SMN2CHRNB4CHRNA3 | |
| SCHEMBL11498525 | 0.68 | FFAR1 (0.40) | CHRNB4CHRNA3HRH1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1707202-A1 | Organic compounds | Speedel Experimenta AG (CH) | 2006-10-04 | — | — | EP | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | CTSV 295/4885CTSL 215/4885CTSB 178/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | CTSV 295/4885CTSL 215/4885CTSB 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.